Avilés, A, Plaza, Z, Sánchez-Alonso, F, Castañeda, S, Fernández-Gutiérrez, B, Diaz-Torne, C, Pilar, FU, González, OM, Gallego, JMS, Giner, E, Cid, AR, Gómez, AP, Nievas, GS, García, J, Juanatey, CG, Llorca, J, González-Gay, MA, Andrés, M. PROGNOSTIC VALUE OF HYPERURICEMIA IN DEVELOPING CARDIOVASCULAR EVENTS IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS: A 10-YEAR PROSPECTIVE STUDY. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.A1239. PMID:. IF:20.600(Q1/1D).

López-Gutiérrez, F, Loricera, J, Tofade, T, Prieto-Peña, D, Romero-Yuste, S, De Miguel, E, Riveros-Frutos, A, Nuñez, DF, Ferraz-Amaro, I, Castañeda, S, Labrador-Sánchez, E, Maiz, O, Garcia, FJN, Galindez-Agirregoikoa, E, González, I, Urruticoechea-Arana, A, Calvo, AR, Moya, P, Unizony, S, Blanco, R. EFFECTIVENESS AND SAFETY OF JANUS KINASE INHIBITORS IN GIANT CELL ARTERITIS. REAL-WORLD CLINICAL PRACTICE STUDY AND LITERATURE REVIEW. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B2775. PMID:. IF:20.600(Q1/1D).

Sanmarti, R, Perez-Garcia, C, de-Toro-Santos, FJ, Alarcon, GS, Escudero-Contreras, A, Cuervo, A, Graell, E, Reina, D, Binstock, EK, Corominas, H, Urionaguena-Onaindia, I, Lasanta, MAL, Alejandro, O, Gomez, MS, Frade-Sosa, B, Novell, RM, Polino, L, Ostiz, JAM, Oreiro, N, Blanco, FJ, Nadales, IP, Ortega-Castro, R, Busquets-Pérez, N, Gómez-Centeno, A, Camacho, O, Cros, JRR, Arciniegas, AMM, Llorente, JFG, Paños, HB, Prior-Español, A, Quiñones, SC, Cruceta, A, Bonfill, E, Gómez, GD, Fàbregas, AR, Maestre, LT, Gomara, MJ, Haro, I. EFFECTS OF ABATACEPT VERSUS HYDROXYCHLOROQUINE ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PALINDROMIC RHEUMATISM: ATWO-YEAR MULTICENTER RANDOMIZED CLINICAL TRIAL. THE PALABA STUDY. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B938. PMID:. IF:20.600(Q1/1D).

López-Gutiérrez, F, Loricera, J, Calabuig, PM, Gil, JJF, González-Mazario, R, Hormigos, C, Freites, D, Laguna, MR, Moya, P, Gómez, ML, Corominas, H, Silva-Díaz, M, Arribas, GG, García-Aparicio, A, Font, J, Casafont-Solé, I, Castaneda, E, Argumánez, CM, Zas, R, Molina-Collada, J, Montero, SR, Melero-González, RB, Galindez-Agirregoikoa, E, Hernández, A, Pantoja, L, Abascal, IB, Jovani, V, Valls-Pascual, E, Mena-Vázquez, N, Gallego, A, Cabaleiro-Raña, N, González, RV, Andrés, M, Castañeda, S. CLINICAL PRESENTATION OF IGG4-RELATED DISEASE. MULTICENTER STUDY AND LITERATURE REVIEW. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B3669. PMID:. IF:20.600(Q1/1D).

De Miguel, E, Dominguez-Alvaro, M, Hernández-Rodríguez, I, Silva-Díaz, M, Otano, JMB, Moya, P, Cabañas, MT, Angeles, VAN, Calvet, J, Casafont-Solé, I, Ivorra, JAR, Labrada-Arrabal, S, Vasques-Rocha, M, Iñiguez, CL, Dorta, AG, Fernández, CC, Villar, MA, Mas, AJ, Prado, FJ, Blanco, R. ACR/EULAR 2022 CLASSIFICATION CRITERIA COMPARED TO THE ACR 1990 CLASSIFICATION CRITERIA IN THE ARTESER REGISTRY OF GIANT CELL ARTERITIS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B849. PMID:. IF:20.600(Q1/1D).

García-Escudero, P, López-Gómez, M, López, BM, Dorta, AG, Frade-Sosa, B, Lizarzaburu, MS, Rúa-Figueroa, I, Fiallo, DV, de Miera, FJTS, Melero-Gonzalez, RB, Santos, DD, Miranda, JA, Belando, CG, Boselli, G, Boteanu, AL, Villalobos, L, Selaya, CC, Santos, CS, Alvarez, ED, Font, J, Alonso, ER, Araguás, ET, Merayo, EE, Rodriguez-Laguna, M, Monjo, I, Gómez, IV, Vela-Casasempere, P, Merino, C, Martínez, MI, Beriain, JAH, Ruiz-Román, A, Calvo-Alén, J. VEXAS syndrome through a rheumatologist's lens: insights from a Spanish national cohort. RHEUMATOLOGY. 2025; 64(6)DOI:10.1093/rheumatology/keaf094. PMID:39937690. IF:4.400(Q1/1D).

Bjorkekjar, HJ, Bruni, C, Broch, K, Brunborg, C, Delgado, PC, Airo, P, Simeon-Aznar, CP, Truchetet, ME, Giollo, A, Balbir-Gurman, A, Martin, M, Denton, C, Gabrielli, A, Del Galdo, F, Vonk, M, Fretheim, H, Bitter, H, Midtvedt, O, Andreassen, A, Hoie, S, Tanaka, Y, Riemekasten, G, Mueller-Ladner, U, Matucci-Cerinic, M, Castellvi, I, Siegert, E, Hachulla, E, Molberg, O, Distler, O, Hoffmann-Vold, AM. INITIAL THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IMPROVES OUTCOMES ACROSS HAEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION: INSIGHTS FROM THE EUSTAR DATABASE. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1890. PMID:. IF:20.600(Q1/1D).

Lopez, BPM, Lopez-Corbeto, M, Zavala, RG, Torrent, RB, Gonzalez-Fernandez, MI, Perello, CM, Sevilla-Perez, B, Fontana, NP, Pascual, AR, Ildefonso, MMS, Regueira, SM, Alcaniz, P, Gonzalez, JCN, Grana, J. TRANSITION IN BONE METABOLISM: INSIGHTS FROM A NATIONAL SURVEY IN SPAIN. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1745. PMID:. IF:20.600(Q1/1D).

Lasanta, MAL, Saborit, MC, Panos, HB, Lizarzaburu, MS, Ruiz-Esquide, V, Vilaseca, DR, Nack, A, Perez-Garcia, C, Bernarde, J, Guillen, AG, Aguilar, JR, Cuervo, A, Valls, M, Gomez, CG, Minguez, S, Novell, RM, Alarcon, PE, Martinez-Morillo, M, Grau, CP, Busquets-Perez, N, Park, HS, Gomez-Puerta, JA, Perez, SH, Palau, NM, Sanmarti, R, Mateo-Soria, L, Diaz-Torne, C, Coromina, H, Alarcon, GS. COMPARISON OF BARICITINIB AND TOFACITINIB EFFECTIVENESS IN RHEUMATOID ARTHRITIS: INSIGHTS FROM A REAL-WORLD COHORT USING PROPENSITY SCORE ADJUSTMENTS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B2477. PMID:. IF:20.600(Q1/1D).

Salman-Monte, TC, Carrion-Barberá, I, Triginer, L, Riveros-Frutos, A, Font, J, Garcia-Villanueva, MJ, Garrote-Corral, S, Galindo, M, Polo, CD, González, IA, Bernabéu, P, Casasempere, PV, Morales, CM, Alvarez, ED, Cortés-Hernández, J, Moreno, SS, Giráldez, CR, Gil, JJF, Hernández, A, Magallares, BP, Garcia, MMP, Cid, CMF, Hernández, S, Ros, I, García-Aparicio, A, Sala-Icardo, L, Gómez-Puerta, JA, Frade-Sosa, B, Garcia-Cirera, S, Bufort, MG, Martínez-Barrio, J, de Salazar, JRG, del Amo, ND, Fito-Manteca, C, Torrente-Segarra, V, Heredia, S, Brandy-Garcia, A, Lucea, ER, Zarrabeitia, LR, Urruticoechea-Arana, A, Pego-Reigosa, JM, Rúa-Figueroa, IJ. AMBISPECTIVE, MULTICENTER REGISTRY OF TREATMENT WITH ANIFROLUMAB IN REAL LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM SPANISH RHEUMATOLOGY DEPARTMENTS (ANIFRO-REU): EFFICACY AND SAFETY AT 3-AND 6-MONTH FOLLOW-UP VISITS. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84DOI:10.1136/annrheumdis-2025-eular.B1338. PMID:. IF:20.600(Q1/1D).

Bjorkekjaer, HJ, Bruni, C, Broch, K, Brunborg, C, Carreira, PE, Airò, P, Simeón-Aznar, CP, Truchetet, ME, Giollo, A, Balbir-Gurman, A, Martin, M, Denton, CP, Gabrielli, A, Del Galdo, F, Vonk, MC, Fretheim, H, Bitter, H, Midtvedt,O, Andreassen, A, Hoie, S, Tanaka, Y, Riemekasten, G, Mueller-Ladner, U, Matucci-Cerinic, M, Castellví, I, Siegert, E, Hachulla, E, Molberg,O, Distler, O, Hoffmann-Vold, AM, EUSTAR Collaborators. A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis. RHEUMATOLOGY. 2025; 64(6)DOI:10.1093/rheumatology/keaf053. PMID:39878955. IF:4.400(Q1/1D).

Ochsenreither, S, Anguera, G, Dieter, S, Trikalinos, N, Fu, SQ, Fernández, BC, Ferrandiz, AC, Kim, SY, Rodriguez, LM, Berg, KCG, Hassan, HIB, Rosholm, A, Fredriksen, AB. Induction of neoantigen-specific immune responses by VB10.NEO in combination with atezolizumab in heavily pretreated patients with advanced solid tumors: Final analysis of the phase 1b VB N-02 trial.. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(16_SUPPL)DOI:10.1200/JCO.2025.43.16_suppl.2639. PMID:. IF:41.900(Q1/1D).

Herbst, RS, John, T, Grohé, C, Goldman, JW, Kato, T, Laktionov, K, Bonanno, L, Tiseo, M, Majem, M, Dómine, M, Ahn, MJ, Kowalski, DM, Pérol, M, Sriuranpong, V, Özgüroglu, M, Bhetariya, P, Markovets, A, Rukazenkov, Y, Muldoon, C, Robichaux, J, Hartmaier, R, Tsuboi, M, Wu, YL. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. NATURE MEDICINE. 2025; 31(6)DOI:10.1038/s41591-025-03577-y. PMID:40097663. IF:50.000(Q1/1D).

Tibau, A, Cliff, ERS, Romano, A, Borrell, M, Molto, C, Kesselheim, AS. Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study. Eclinicalmedicine. 2025; 84DOI:10.1016/j.eclinm.2025.103088. PMID:40687736. IF:10.000(Q1/1D).

Jiménez-Vicente, C, Arribas, I, Pomares, H, Ramil, G, Castaño-Diez, S, Pérez-Valencia, AI, Sturla, AL, López-Guerra, M, Martinez-Roca, A, Zugasti, I, Guijarro, F, Cortés-Bullich, A, Merchán, B, Triguero, A, Monge, I, Tuca, A, Oñate, G, Garrido, A, Sierra, J, Arnan, M, Esteve, J, Díaz-Beyá, M. Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia. HAEMATOLOGICA. 2025; 110(6)DOI:10.3324/haematol.2024.286589. PMID:39844754. IF:10.100(Q1/2D).

Barroeta, I, Videla, L, Carmona-Iragui, M, Fortea, J, Rafii, MS. Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70258. PMID:40528298. IF:11.100(Q1/1D).

Sauer, M, Gomes, BF, Shahrouki, P, Lantero-Rodriguez, J, Montoliu-Gaya, L, Camporesi, E, Belbin, O, Alcolea, D, Kumar, A, Sharma, M, Singh, S, Brinkmalm, G, Gobom, J, Carmona-Iragui, M, Schöll, M, Janelidze, S, Deep, G, Blennow, K, Zetterberg, H, Brinkmalm, A, Lleó, A, Fortea, J, Hansson, O, Ashton, NJ, Nilsson, J. Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70241. PMID:40522075. IF:11.100(Q1/1D).

McGlinchey, E, Ranchod, K, Stroebel, R, Lusizi, B, Galvin, M, Kleinhans, AV, Fortea, J, Hoffman, J, Makanya, S. Bridging perspectives: The value of collaboration between Traditional Healing Practitioners and Medical Doctors in dementia research and care in South Africa. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70370. PMID:40566835. IF:11.100(Q1/1D).

Ramos, JR, Perrín, RS, Martín, MAG, Clemente, YC, Díez, MA, Pinto, AD, Díaz, AS, Almela, AFD, Serrano, PS, Grande, ASL, Blanco, CC. Adverse drug events associated with emergency departments visits. EMERGENCIAS. 2025; 37(3)DOI:10.55633/s3me/025.2025. PMID:. IF:6.300(Q1/1D).

Delaby, C, Ladang, A, Martinez-Yriarte, J, Zecca, C, Logroscino, G, Koertvelyessy, P, Tumani, H, Parchi, P, Quadrio, I, Hart, M, Olsen, DA, Alcolea, D, Blennow, K, Fortea, J, Lleo, A, Algeciras-Schimnich, A, Ayrignac, X, Bedel, A, Santos, GAA, Borelli, W, Bouaziz-Amar, E, Baldeiras, I, Bigot-Corbel, E, Bjerke, M, Perez, MC, Casoli, T, Chabrashvili, T, Chapman, MD, Cusato, J, Dursun, E, Fourier, A, Galimberti, D, Gezen-Ak, D, Gordon, BA, Gouju, J, Florez, SD, Sanchez, JH, Herwerth, M, Imperiale, D, Kaczorowski, F, Kasuga, K, Keshavan, A, Khalil, M, Kuhle, J, Leithner, C, Lewczuk, P, Letournel, F, Tsolaki, M, Giuffre, GM, Blanc, MC, Mroczko, B, Rodriguez, JEM, Musso, G, Kulczynska-Przybik, A, Nogueira, L, Paquet, C, Baiardi, S, Gaetani, L, Parnetti, L, Garay, RP, Poesen, K, Quillard-Muraine, M, Borja, ER, Schraen, S, Terracciano, D, Bachhuber, F, Halbgebauer, S, Tzartos, S, Tzartos, J, Unterwalder, N, Vermunt, L, Wellington, CL, Zetterberg, H, Teunissen, C, Lehmann, S. Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70343. PMID:40551293. IF:11.100(Q1/1D).